Navigation Links
Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology

Catalyst to Provide Proprietary Protein and Small Molecule Products for the Generation and Differentiation of Genomically-Unaltered Induced Pluripotent Stem (iPS) Cells

LA JOLLA, Calif. and BOSTON, April 23 /PRNewswire/ -- Fate Therapeutics, Inc. and Stemgent, Inc. announced today the formation of Catalyst, a collaborative one-of-a-kind program to provide pharmaceutical and biotechnology companies with the most advanced induced pluripotent stem (iPS) cell technology platform for drug discovery and development.

Catalyst will include the revolutionary protein-based reprogramming technology pioneered by Sheng Ding, Ph.D., published for the first time today in Cell Stem Cell. Dr. Ding, an associate professor of The Scripps Research Institute and scientific founder of Fate Therapeutics and Stemgent, is the first to report the creation of iPS cells using cell-penetrating proteins, a technique that effectively eliminates any risk of genetic modification. Catalyst will also include pioneering discoveries by Rudolf Jaenisch, M.D., a founding member of the Whitehead Institute, scientific founder of Fate Therapeutics and scientific advisory board member of Stemgent, who last month produced the first Parkinson's disease patient-derived iPS cells free of viral reprogramming factors.

In exchange for annual funding, Catalyst member companies will gain exclusive access to proprietary iPS cell technology, including specific iPS-derived cells for toxicity testing and primary screening. Fate Therapeutics and Stemgent will jointly guide and share the expenses of the development of products under Catalyst.

Revolutionary Products Available for First Time

"The creation of Catalyst represents the first time that many of these cutting edge technologies will be made available to industry," said Ian Ratcliffe, Stemgent's president and chief executive officer. "Dr. Ding's ground-breaking methods using proteins and small molecules to generate iPS cells and Dr. Jaenisch's innovative generation of a new way to model Parkinson's disease are just a few examples of the revolutionary products that will be made available - in commercial grade quality, reliability and scale - to Catalyst members."

Fate Therapeutics continues to be the leader in developing small molecules and biologics to modulate cell fate for regenerative medicine and therapeutic reprogramming indications, including hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. Stemgent accelerates the translation of stem cell science by providing application validated, proprietary reagents and tools developed by some of the world's leading stem cell scientists.

Commenting on Catalyst, Mr. Ratcliffe said, "Fate Therapeutics' stem cell biology expertise and Stemgent's superior reagent design and production capabilities make Catalyst an unmatched opportunity for the development of optimized small molecules and protein reagents for efficient and reproducible iPS cell generation and differentiation."

"Catalyst is the sole industry opportunity to access the most advanced iPS cell technology platform," said Paul Grayson, Fate Therapeutics' president and chief executive officer. "The Catalyst program represents a unique business collaboration amongst its participants to accelerate the translation of iPS cell technology into the discovery and development of safer and more effective therapeutics."

iPS cells are made by "reprogramming" fully differentiated mature cells, such as adult skin cells, to become pluripotent or stem-cell like and do not rely on the use of stem cells derived from embryos. Because iPS cells can differentiate into any cell type, iPS cells are considered of great importance to medicine because they can be used to model human diseases, discover and test drug candidates and develop personalized cell therapies. Previously, iPS cell generation required the delivery of genetic material through viruses or plasmids, which carry risks from insertion and are time-consuming, inefficient methods. Now, in collaboration with Dr. Ding, Fate Therapeutics and Stemgent have developed small molecules and proteins for the safe and efficient creation of high quality iPS cells that can reproducibly differentiate into essential cell types for drug discovery and development.

"Catalyst's technology - creating and differentiating iPS cells into distinct cell types - will uncover the essential epigenetic and gene expression profiles associated with the derivation of specific cell lineages," said Mr. Grayson. "These same technologies will prove critical in our discovery and development of conventional pharmaceuticals to guide cell fate for therapeutic benefit."

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating stem cell biology to develop therapeutics based on modulating cell fate and to enable a new drug discovery paradigm with the Company's proprietary induced-pluripotent stem (iPS) cell technology. The Company's first therapeutic candidate is scheduled to enter clinical trials in early 2009 in hematopoietic reconstitution. Fate Therapeutics is a private biotech company headquartered in La Jolla, CA. For more information, please visit

About Stemgent, Inc.

Stemgent advances stem cell science by providing proprietary reagents and tools developed by some of the world's leading stem cell scientists. Stemgent's product offering has been specifically optimized for and screened against stem cells, and includes small molecules for pluripotency, self-renewal, and differentiation, viral-delivered transcription factors, matrices, cell lines, cytokines, antibodies, transfection reagents, and more. This unique product mix is designed to serve researchers who study stem cell biology and regenerative medicine, and those who use cells derived from stem cells as tools to advance their understanding of major diseases. With dual headquarters in Boston, MA, and San Diego, CA, Stemgent is well positioned to serve these major research markets. For more information, please visit

Fate Therapeutics and Stemgent, along with Genzyme, Burrill & Company and WIRED Magazine, will be featured in a panel presentation entitled "Mastering Your (Cell) Fate: Stem Cells, iPSCs and the Future of Medicine" on May 18, 2009 at 2 p.m. at the 2009 BIO International Convention in Atlanta, GA.

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 On October ... the Congressional Record her statement recognizing the third annual ... 11-17. IPAW is sponsored by the Plasma Protein ... is designed to:   , Raise global awareness ... plasma donors in saving and improving lives , ...
(Date:10/9/2015)... Governor Tom Wolf announced today ... on developing T-cell receptor cancer immunotherapy treatments, will create ... expansion project. Pennsylvania , and ... 110 new, high-paying jobs will be created with this ... proposal includes sustained funding for the life science sector ...
(Date:10/9/2015)... HERSHEY, Pa. and ROCKVILLE, ... Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing ... today announced that it has entered into an ... on LAMP-vax products for the treatment or prevention ... Upon execution of the agreement, Immunomic Therapeutics will ...
(Date:10/9/2015)... , Oct. 9, 2015  DePuy Synthes Trauma* announced ... with Q-PACK ®  Technology**, the only pre-hydrated demineralized ... extremity procedures (foot and ankle, hand and wrist), including ... made here at the 2015 Orthopaedic Trauma Association (OTA) ... natural scaffold for new bone growth) and osteoinductive 2,3 ...
Breaking Biology Technology:
... Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference ... provide a company overview at 11:00am EDT , Wednesday, June 9, 2010 at ... , , ... , , , ...
... June 1 Diplomat Specialty Pharmacy, the ... launch of Navigator Health Services, an independent division of ... pharmacy industry. The announcement was made by Diplomat Specialty ... who says that Navigator Health Services was formed in ...
... Calif. , June 1 Epeius Biotechnologies Corporation ( ... "Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as ... the ASCO Annual Meeting on June 8, 2010 . The ... Stanford University Medical Center, Palo Alto CA. ...
Cached Biology Technology:
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant ... Clinic Wellness to create an interactive, image-based health ... health and wellness kiosk.  The unique assessment quantifies ... a number that suggests an individual,s biological age ... values as measured by the kiosk. ...
(Date:9/8/2015)... , Sept. 8, 2015   TREW Marketing ... the new survey, Smart Marketing for Engineers TM ... 580 engineering professionals reveals insightful findings about engineers, preferences ... types of content engineers most value and trust, and ... Marketers targeting technical audiences grapple with how to ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... key concern for enterprises, banks, government organizations, telecommunications, ... and numeric keypads were previously being used to ... introduction of two-factor authentication, wherein individuals could gain ... two different components, such as hardware devices and ...
Breaking Biology News(10 mins):
... "We can make you and we can break you." If ... oxide would start something like that. But this song wouldn,t ... of Rice chemist James Tour demonstrates an environmentally friendly way ... version of single-atom-thick graphene expected to find use in all ...
... A novel approach detects genetically abnormal cells in the blood ... in tumor cells and increase in number with the severity ... The University of Texas MD Anderson Cancer Center report in ... patients in the study also had many times the number ...
... A University of Minnesota Medical School research team led ... a novel approach to ease the chronic and acute ... a mouse model of SCD, Gupta and University of ... that exhibited both musculoskeletal pain and temperature sensitivity, symptoms ...
Cached Biology News:
... apoptosis and mitochondrial membrane potential. The mitochondrial ... of the initiation of cellular apoptosis. This ... in the electrochemical gradient across the mitochondrial ... the membrane potential (YD). Loss of mitochondrial ...
... AVOID FREEZE/THAW CYCLES. An assay kit ... by Western blotting. PARP is an enzyme ... During apoptosis, PARP is cleaved by caspase-3. ... kDa to 85 kDa is a hallmark ...
... Identical to the DH-2000, but comes with ... switch up to 5 Hz) The ... the continuous spectrum of deuterium and tungsten halogen ... combined-spectrum light source produces a powerful, stable output ...
... MSD Security ChemStation is ... software application for data ... library searching and reporting, ... of data security, integrity, ...
Biology Products: